TABLE 3.
Time (min) | Glimepiride |
|
---|---|---|
Placebo | Diazoxide | |
−60 | 0.0 | 0.0 |
−30 | 0.0 | 0.0 |
0 | 0.1 ± 0.1 | 0.2 ± 0.1 |
15 | 0.2 ± 0.1 | 0.2 ± 0.1 |
30 | 0.3 ± 0.2 | 0.2 ± 0.1 |
45 | 0.5 ± 0.2 | 0.1 ± 0.1 |
60 | 0.7 ± 0.2 | 0.3 ± 0.2 |
75 | 0.8 ± 0.2 | 0.3 ± 0.2 |
90 | 0.9 ± 0.2 | 0.2 ± 0.1 |
105 | 1.3 ± 0.2 | 0.5 ± 0.2 |
120 | 1.8 ± 0.4 | 0.9 ± 0.3 |
135 | 2.0 ± 0.4 | 1.3 ± 0.4 |
150 | 2.4 ± 0.5 | 1.4 ± 0.4 |
165 | 2.5 ± 0.5 | 2.2 ± 0.2 |
180 | 2.5 ± 0.5 | 2.0 ± 0.2 |
(P < 0.0001) |
*Mean ± SE data (mg · kg−1 · min−1) are shown for oral administration of placebo or diazoxide (6.0 mg/kg) at −30 min and oral glimepiride (4.0 mg) at 0 min. To convert mg · kg−1 · min.−1 to μmol · kg−1 · min−1, multiply by 5.551.